PRLD
Prelude Therapeutics IncCompany with tickers: PRLD
CIK
1678660
CUSIP
74065P101
Shares Outstanding
64,917,172
13F Activity (30d)
53 filings
52 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $4,580,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $18,757,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $13,601,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-14,177,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-10,385,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.13 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.13 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |